It is colorectal cancer or colon cancer. third The most common cancer in the world; The third most common in men and the second most common in women.

A recent small-scale analgesic drug test in the United States showed excellent results: tumors were lost in 100 percent of participants.

What is colorectal cancer?

Colorectal cancer (CRC) is a disease in which cells in the colon or rectum grow out of control. It is sometimes called colon cancer. The colon is the large intestine or large intestine. The anus is the passage that connects the colon to the anus.

CRC symptoms include:

  • Constant change in bowel habits
  • Bleeding from the last passage, or blood in the stool
  • Unexplained weight loss or fatigue
  • Unexplained abdominal pain
  • Any new swellings, swelling or lumps in the abdomen

Any of these symptoms should be discussed with a health professional. It may not be difficult at all, but if it is cancer, getting it early will greatly improve your chances of getting better.

A.D. By 2020, there were more than 1.9 million new CRC cases. CRC Global Burden 60 percent By 2030, more than 2.2 million new cases and 1.1 million people will die.

Treatment for people with colorectal cancer often includes the following.

  • Surgery: amputation of the intestinal tract; This is the most effective way to treat colon cancer.
  • Chemotherapy drugs to kill cancer cells
  • Radiotherapy using radiation to kill cancer cells

Due to the growing number of cases of this disease and the burden on patients and health systems, new and effective treatments are urgently needed.

What does the new study show?

Scientists and healthcare professionals are thrilled with the new Research It was published in June in the New England Journal of Medicine. The study, conducted at the Memorial Sloan Catheter Cancer Center in New York, was followed by 12 patients with specific anal cancer who were given the new drug Dostarlimab, developed by the pharmaceutical company Glassomis Klein.

The drug was given to patients at a cost of $ 11,000 every three to six months. Some participants had regular chemotherapy and surgery, but this could be skipped for people who responded well to the medication.

At the end of their treatment, all 12 participants were confirmed to be in remission, and no signs of cancer were detected by physical examination and scan.

The type of cancer being treated is MMRd, which is the most common type of anal cancer in the area. Unrelated repair genes are involved in debugging errors when DNA is copied into a cell. When there is a defect, like these tumors, DNA mutation can occur and lead to cancer.

Dostarlimab is a group of drugs called the anti-PD1 monoclonal antibody. These special glandular cells have special immunosuppressive properties called PD-1, which regulates the T-cells that are needed to destroy them. Dostarlimab, an anti-PD1, interferes with this process so that cancer cells cannot protect themselves from T-cells and the immune system can attack and kill them.

The new study will take a step towards the ultimate goal of cancer treatment, to provide individual care for the tumor for each patient. Everyone’s cancer cells have a subtle difference in the type of mutation, by giving the drug specific drugs to the individual and, most importantly, improving the patient’s unique mutation.

The side effects of the drug have been reported to be minimal, but it is not yet known how long the participants will be free of cancer, so scientists have not yet been able to call it a cure.

This type of immunosuppressive treatment reduces the need for surgery and chemotherapy for future cancer patients, especially young people. Both chemotherapy and radiotherapy can be particularly detrimental to fertility, for both males and females, eggs and sperm should be frozen where possible and then manually fertilized and planted. Bowel surgery poses a risk for cancer itself, and many patients find it difficult to open their bowel after a stoma bag and / or going to the toilet. If Dostarlimab reduces the need for all these other treatments, we will see an improvement in the quality of life of people being treated for stomach cancer.

How can we reduce our risk of colorectal cancer?

Diagnosis of any type of cancer is never an individual’s fault and should not make people feel that way. Inevitable factors such as genetics often play a big role, and if you have a strong family history, you may need regular follow-up by a health care team if you have colorectal cancer. People with other bowel problems, such as inflammatory bowel disease, may be at increased risk for CRC and should be especially vigilant for any new and unknown symptoms.

However, there are things we can all do to reduce the risk of CRC. There is evidence that eating red and boiled meat, including beef, lamb, pork and goat, increases the risk of colon cancer, so we should try to limit our intake to one or two servings a week. Eating a lot of fiber such as whole grains, oats, chickpeas, lentils and beans has been shown to reduce our risk of colon cancer and we need to eat about 30 grams a day.

Obesity is linked to colon cancer, so maintaining a healthy weight reduces our risk of developing the disease. People who exercise are less likely to develop colon cancer. Alcohol is associated with seven types of cancer, including colon cancer. Smoking is associated with colon cancer, so quitting smoking not only reduces the risk of this cancer but also many other health problems.

Many countries have developed screening programs to help diagnose colon cancer in the early stages before the onset of symptoms. If you have been tested as part of a screening program, which may include sampling, please do so. The earlier these items are available, the better your chances of survival.

And finally, never be ashamed to talk to a health care professional about your bowel habits; We are used to it and we need to know if you have any changes. Remember, it may not be difficult, but it is better to know before you wait.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *